Fresenius SE & Co KGaA (XTER:FRE)
€ 33.2 -0.28 (-0.84%) Market Cap: 18.70 Bil Enterprise Value: 29.09 Bil PE Ratio: 0 PB Ratio: 1.04 GF Score: 61/100

Fresenius SE & Co KGaA at JPMorgan Healthcare Conference Transcript

Jan 13, 2020 / 05:30PM GMT
Release Date Price: €49.48 (-1.00%)
David James Adlington
JP Morgan Chase & Co, Research Division - Head of Medical Technology and Services Equity Research

Good morning, everybody. I'm David Adlington. I head up the European Medtech and Services Research Group in London. It's my pleasure to introduce Stephan Sturm, CEO of Fresenius SE. The breakout room afterwards is at Yorkshire Room, just down the corridor that way. Stephan, thank you.

Stephan Sturm
Fresenius SE & Co. KGaA - CEO, President & Chairman of Management Board - Fresenius Management SE

David, thank you. Good morning, everybody. Thank you for your interest in Fresenius. Much appreciated as always. Also, as always, no slides to distract you, you will have to focus to my -- on my speech. Thank you.

We have concluded our investment year 2019. And it's a bit too early to tell you something definitive as to the outcome. But I would work on the assumption that when we publish our results on February 20, it is very unlikely that we're going to create a major surprise.

To remind you all, the guidance that we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot